delete National Health (Pharmaceutical Benefits) Amendment Regulations 2004 (No. 1)
Amendment to the National Health (Pharmaceutical Benefits) Regulations governing Australia's Pharmaceutical Benefits Scheme (PBS), which subsidizes the cost of medicines for Australian residents. The regulations establish pricing mechanisms, approval processes for listed medicines, pharmacy dispensing requirements, and patient copayment structures. This 2004 Amendment (No. 1) made substantive changes to the PBS regulatory framework.
This instrument perpetuates and expands the PBS regulatory framework which: (1) Distorts pharmaceutical markets through government-mandated pricing that suppresses prices below market equilibrium, reducing supply incentives and innovation in medicines for the Australian market; (2) Creates monopsony-style buyer power with the government as the primary drug purchaser, distorting normal commercial relationships between manufacturers, pharmacies, and consumers; (3) Imposes substantial fiscal burdens on taxpayers through subsidies while creating moral hazard that encourages overconsumption of subsidized medicines; (4) Generates extensive compliance costs for pharmaceutical manufacturers and pharmacies that are passed on to consumers, reducing competitiveness in the healthcare sector; (5) The PBS listing approval process adds bureaucratic delays that restrict patient access to new treatments; (6) Rural and remote pharmacies bear disproportionate compliance burdens due to geographic distance and logistics. While the PBS may help some individuals afford medicines, it achieves this through market distortion rather than increasing overall prosperity, and the unintended consequences of price controls, supply restrictions, and moral hazard outweigh the benefits.